Exelixis, Inc. (BIT:1EXEL)

Market Cap	8.75B
Revenue (ttm)	1.90B
Net Income (ttm)	512.86M
Shares Out	n/a
EPS (ttm)	1.77
PE Ratio	17.06
Forward PE	12.15
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	10
Open	32.10
Previous Close	32.10
Day's Range	32.10 - 32.10
52-Week Range	31.86 - 42.61
Beta	n/a
RSI	17.33
Earnings Date	Aug 5, 2025

About Ligand Pharmaceuticals

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1994
• Employees: 1,147
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1EXEL

Financial Performance

In 2024, Exelixis's revenue was $2.17 billion, an increase of 18.49% compared to the previous year's $1.83 billion. Earnings were $521.27 million, an increase of 150.89%.